東曜藥業-B(01875.HK)公開發售超購11.95倍 8日上市
格隆匯11月7日丨東曜藥業-B(01875.HK)公佈,公司全球發售9000萬股,其中香港發售900萬股佔10%,國際發售8100萬股佔90%;每股定價6.55港元,為招股價範圍(6.55港元-7.55港元)下限,集資淨額約5.11億港元;1手中籤率15.00%;預計11月8日掛牌。
公開發售合共接獲約2.64萬份有效申請,認購合共約1.17億股公開發售股份,相當於公開發售初步可供認購的900萬股超額約11.95倍。國際發售已獲適度超額認購。
基石投資者方面,晟德大藥廠、Vivo Capital及年興維京羣島各自已分別認購598.2萬股、1196.44萬股及598.2萬股,總計為2392.84萬股發售股份,合共佔緊隨全球發售完成後公司已發行股本約4.20%及全球發售下的發售股份數目約26.59%,在各情況下均假設超額配股權未獲行使。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.